Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment.
about
New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNAReview of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyHepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain.Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assayHBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b.Significance of viral status on prognosis of hepatitis B-related hepatocellular carcinoma after curative resection in East Asia.Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analogue treatment.Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients.Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.JSH Guidelines for the Management of Hepatitis B Virus Infection.Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance.Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection.Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Anti-hepatitis B virus therapy: To stop, or not to stop: Has the question been solved?Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels.Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B.Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.Viral Biomarkers in Chronic HBeAg Negative HBV Infection
P2860
Q24675792-33615A3B-3071-4FC4-B3EA-6305D1A9C24FQ26740161-11F93C04-787B-49DD-8AAD-7AA1F970C948Q31158133-18FF1468-2ECF-4DE3-9FCD-119522FB9F77Q36314552-1A3C07CE-6542-4ECE-8C66-98940029485DQ37135543-327D7A7D-D0E7-42F5-B1E9-541DA69D2871Q37255017-1455B509-75D0-4D7E-A506-6A3A2200067FQ38413432-3F60A5D4-C092-4E2A-80FE-FEABBE1A5642Q38596871-256E1AA2-5E7D-4640-8AD5-BDA146255159Q38815530-E2044FE3-8709-4DD5-A9F8-E9FEC1C82CCFQ40189344-8E4539D4-5EB4-479A-B269-F8245D350CD7Q40404314-986EEA24-5574-48F5-9650-758499654F82Q40582667-52B43B72-740A-4A88-8CC1-C54934EE10DCQ41669068-90877F9E-A9B2-455E-9314-0B78CE863A51Q42244740-5E301B2F-818B-4FDF-B2D0-A410FE8A21D5Q43569399-C19F728B-F9E1-4FF4-A742-924EEFFC2F16Q44082487-818D3206-5BC5-4E23-AEEC-96D69724F41FQ44329278-F02B2C53-AB6C-4769-8854-3024161912EFQ45326295-E43F1A6D-2FB0-4BEE-AEAD-0FD4A80D0C4DQ45355602-44EE0724-DD94-4859-8D45-AC799163E8A4Q45388432-03DF022D-B471-4281-93EE-941164E72550Q46200437-48A12173-352C-474B-B2AB-4122499088FBQ46720186-9D6B3996-3D73-450C-A4AA-D76EA3B8D70BQ47569813-9EC8A120-B817-4289-89FF-7E945980CD77Q47890590-F7C198E2-3365-4956-B491-9FF8CC958F13Q59126856-AEAFB36B-C937-4708-8362-891987331C98
P2860
Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Clinical evaluation of a new e ...... nitoring lamivudine treatment.
@en
Clinical evaluation of a new e ...... nitoring lamivudine treatment.
@nl
type
label
Clinical evaluation of a new e ...... nitoring lamivudine treatment.
@en
Clinical evaluation of a new e ...... nitoring lamivudine treatment.
@nl
prefLabel
Clinical evaluation of a new e ...... nitoring lamivudine treatment.
@en
Clinical evaluation of a new e ...... nitoring lamivudine treatment.
@nl
P2093
P2860
P1476
Clinical evaluation of a new e ...... nitoring lamivudine treatment.
@en
P2093
Kiyosawa K
Matsumoto A
Rokuhara A
P2860
P304
P356
10.1046/J.1365-2893.2003.00437.X
P577
2003-07-01T00:00:00Z